Should You Obtain a Repeat Echocardiogram Now?
Yes, obtain a repeat transthoracic echocardiogram now—your patient's last study was performed in [DATE], and current ACC/AHA guidelines recommend surveillance echocardiography every 1–2 years for asymptomatic Stage B moderate aortic regurgitation. 1
Surveillance Interval for Moderate Aortic Regurgitation
For asymptomatic moderate aortic regurgitation (Stage B), repeat transthoracic echocardiography is recommended every 1–2 years to monitor for progression. 1
The 2019 JACC natural history study of Stage B aortic regurgitation demonstrated that patients with baseline moderate AR had a 53% 10-year incidence of progression to severe disease (Stage C/D), with annualized progression rates of 4.2 mm²/year for effective regurgitant orifice area and 9.9 mL/year for regurgitant volume. 2
A 2017 Echo Research and Practice study found that 10% of patients with mild-to-moderate AR showed progression over an average follow-up of 4.0 ± 2.6 years, with 2.3% progressing to severe AR. 3
What to Assess on the Repeat Study
Quantitative hemodynamic parameters must be measured—not just qualitative jet assessment—to accurately track progression and guide timing of intervention. 1, 4
Measure effective regurgitant orifice area (EROA) and regurgitant volume (RVol) using the proximal isovelocity surface area (PISA) method or vena contracta width. 5, 1
Assess left ventricular end-systolic volume index (LVESVi) and volume-derived ejection fraction using the disk-summation method. 6, 4
A 2021 JAMA Cardiology study demonstrated that LVESVi >45 mL/m² was independently associated with increased mortality risk (HR 1.93,95% CI 1.10–3.38) in asymptomatic patients with hemodynamically significant AR, and this volumetric threshold superseded traditional linear LV dimensions. 6
A 2008 JACC Cardiovascular Imaging prospective study established that quantitative AR grading (QASE-severe: RVol ≥60 mL/beat or ERO ≥30 mm²) was an independent predictor of survival and cardiac events, with 10-year cardiac event rates of 63% versus 21% for severe versus mild AR. 4
Additional Imaging Considerations
If your patient has a bicuspid aortic valve (present in approximately 50% of moderate AR cases), cross-sectional imaging with MRI or CT angiography is recommended for ascending aortic surveillance. 1
Bicuspid valve patients have higher progression rates—the 2017 study showed 15% progression in mixed valvular pathology versus 5% in isolated AR. 3
Clinical Context
Your patient's preserved LVEF of 59% and normal IVC pressure are reassuring, but these parameters alone do not obviate the need for serial imaging to detect early LV remodeling before irreversible dysfunction develops. 1, 6
Transthoracic echocardiography remains the first-line imaging modality for valvular regurgitation assessment. 5
Common Pitfalls to Avoid
Do not rely solely on color Doppler jet area for severity grading—it is not recommended for quantifying AR severity. 5
Do not use beta-blockers for blood pressure control in AR, as they prolong diastole and increase regurgitant volume. 1
Do not delay surveillance imaging beyond the 1–2 year window, as progression can be rapid and unpredictable, particularly in bicuspid valve disease. 1, 2